Skip to content

A prospective observational study on evaluating the effectiveness of monotherapy and combination therapy in the treatment of CRE bacteremia

A study for the key strategies of early warning and intervention of carbapenem-resistant Enterobacteriaceae

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021093
Enrollment
Unknown
Registered
2019-01-28
Start date
2019-02-11
Completion date
Unknown
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bacterial infection

Interventions

Group 1:monotherapy
Group 2:Combined therapy

Sponsors

Peking University People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) informed consent was signed; (2) in the course of treatment, there is a definite monotherapy or combination therapy for anti-infection; (3) the results of the first blood culture were CRE positive; (4) when blood culture was carried out, the effective treatment time of anti-infection was not more than 48 hours.

Exclusion criteria

Exclusion criteria: (1) failure to sign informed consent; (2) patients with secondary bacteremia whose blood culture results were positive for CRE; (3) when blood culture was carried out, the effective treatment time of anti-infection was more than 48 hours.

Design outcomes

Primary

MeasureTime frame
30-day all-cause mortality;

Secondary

MeasureTime frame
clinical symptoms;clearance rate of CRE;

Countries

China

Contacts

Public ContactHui Wang

Peking University People's Hospital

whuibj@163.com+86 010-88326301

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026